Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.53 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 15/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634621 | 0.94 | PRKDC (0.51) | PRKDCSLC40A1FAAH | |
| SCHEMBL17634920 | 0.93 | PRKDC (0.50) | PRKDCSLC40A1FAAH | |
| SCHEMBL17634659 | 0.93 | PRKDC (0.49) | PRKDCSLC40A1FAAHALDH1A1CYP1A2 | |
| SCHEMBL17634630 | 0.93 | PRKDC (0.49) | PRKDCSLC40A1FAAHALDH1A1CYP1A2 | |
| SCHEMBL19355548 | 0.93 | PRKDC (0.49) | PRKDCSLC40A1FAAHALDH1A1CYP1A2 | |
| SCHEMBL17634795 | 0.92 | PRKDC (0.54) | PRKDCSLC40A1FAAHALDH1A1CYP1A2 | |
| SCHEMBL15339608 | 0.92 | PRKDC (0.54) | PRKDCSLC40A1FAAHALDH1A1CYP1A2 | |
| SCHEMBL15339618 | 0.92 | PRKDC (0.54) | PRKDCSLC40A1FAAHALDH1A1CYP1A2 | |
| SCHEMBL15339643 | 0.92 | PRKDC (0.49) | PRKDCSLC40A1FAAH | |
| SCHEMBL17634654 | 0.92 | PRKDC (0.51) | PRKDCSLC40A1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258789-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258789-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.